E

New developments on the T cell engager front

Update on the T cell engager niche with an emerging agent of interest

July 8, 2021
E

Tackling a hostile tumour microenvironment on multiple fronts

Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME

June 24, 2021
E

Dancing with proteins at the Masquerade

Who's going to the masquerade ball and how might they fare in the future?

June 1, 2021
E

Off the Beaten ASCO21 Track Part 1

Hidden early stage gems to watch out for at ASCO21

May 25, 2021
E

Digging deep on SHP2 and KRAS

New developments on the KRAS and SHP2 front

May 17, 2021
E

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021
E

Tooting the DDR horn

Bridging the DDR gap from AACR to ASCO

May 7, 2021
E

The battle of protein degraders versus inhibitors continues apace

Who's going to win in the battle between protein degraders and small molecule inhibitors?

May 4, 2021
E

Can a monoDAC hit the groove against IMiDs and CELMoDs?

What can we learn from C4 Therapeutics monoDAC, CFT7455?

April 28, 2021
E

A twist in chemical moeity

A look at the subtleties and nuances under the hood of the Arvinas PROTACs

April 27, 2021
E

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021
E

Targeting Menin and the evolving landscape for NPM1-MLLr acute leukemias

A look at new data in the Menin/MLLr inhibitor landscape in acute leukemias

April 20, 2021
E

Novel approaches to cell therapies – Part 1

A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.

April 19, 2021
E

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021
E

AACR21 Preview 8 – The growing bispecific niche

A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting

April 8, 2021
E

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021
E

AACR21 Preview 6 Exploring a novel and early target for cancer therapeutics

A look at a potential emerging target which could be druggable

March 30, 2021
E

AACR21 Preview 5 Promising new developments in the PARP field and beyond

What's hot on the DDR front and PARP inhibitor space at AACR21?

March 25, 2021
E

Fifteen AACR21 On Demand Presentations To Watch

Noteworthy AACR21 on-demand presentations.

March 23, 2021
E

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021
E

Novel combination strategies to enhance KRAS inhibitors

Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!

March 16, 2021
E

The King of Kings

Capturing attention in the crowded protein degradation niche

March 11, 2021
E

AACR21 Preview 1 Emerging targets for protein degradation and molecular glues

What to watch out for in the protein degradation niche

March 11, 2021